China Biotech News: Deals, Approvals & Policy

How to Use This Digest

The volume of China biotech news has become unmanageable for anyone who is not reading it full-time. A single quarter now brings dozens of out-licensing deals, scores of NMPA decisions, and a steady churn of IPO filings and policy notices. Most of it is noise to a dealmaker; a small fraction reshapes where value is created and how it can be captured across the border.

This page is our filter. We organize the news by theme — deals, approvals, capital markets, policy, and company moves — date the items, and attach a one-line “why it matters” to each so you can skim for signal. It is deliberately a rolling resource, refreshed as the landscape shifts; the date stamp at the top tells you how current it is. Where a topic deserves more than a line, we link to the dedicated tracker. For the deal-by-deal record, pair this with our China outbound licensing tracker and the annual China out-licensing report.

The Big Picture (June 2026)

If you read only one paragraph: 2025 was the year China’s biopharma sector stopped being a story about potential and became a story about throughput. Chinese drugmakers signed a record ~$136 billion in outbound licensing deals across roughly 157 transactions — about a third of all global licensing spend, and up sharply from ~$52 billion across 94 deals in 2024, according to industry deal trackers. Total upfront value rose roughly fourfold from 2022 levels, signalling that multinationals are no longer treating China as a bargain basement but as a primary source of differentiated assets.

On the regulatory side, the NMPA approved a record ~120 new drugs, and for the first time domestic developers contributed more approvals than foreign arrivals. On the capital side, the Hong Kong listing window reopened with force. And on the policy side, the United States enacted the long-debated BIOSECURE Act — a reminder that the geopolitical overhang is real even as the commercial integration deepens. The throughline for dealmakers: the supply of licensable, de-risked Chinese assets is rising faster than the channels to access them are maturing.

Out-Licensing & M&A

The deal flow is where China biotech news is loudest. A selection of the items that defined 2025 into 2026, each with the dealmaker’s read:

• AstraZeneca–CSPC — obesity (late 2025). Up to ~$18.5B across eight obesity and type 2 diabetes programs, with roughly $1.2B upfront. Why it matters: the largest China licensing pact of the cycle, and proof that the GLP-1 demand wave is pulling buyers into Chinese metabolic pipelines at the very top of the market.
• AstraZeneca–CSPC — chronic disease (June 2025). An earlier AI-enabled research collaboration worth up to ~$5.2B. Why it matters: shows a single multinational building a multi-deal, platform-level relationship with one Chinese partner rather than a one-off asset grab.
• GSK–Hengrui (2025). Up to ~$12B in potential milestones across up to 12 programs (respiratory, immunology/inflammation, oncology), anchored by a PDE3/4 inhibitor for COPD, with ~$500M upfront. Why it matters: a Big Pharma betting on the breadth of one Chinese pipeline, not a single molecule.
• Pfizer–3SBio (2025). Ex-China rights to PD-1/VEGF bispecific SSGJ-707 for a record $1.25B upfront (plus up to ~$4.8B milestones and a $100M equity stake). Why it matters: the largest upfront ever for a Chinese-origin therapy — the clearest single data point that the market has re-rated Chinese assets.
• Merck–Kelun-Biotech (ADC franchise). A multi-deal ADC relationship whose largest single agreement (their third, a seven-ADC pact) reached up to ~$9.3B in potential value. Why it matters: the template for how a Western leader can build an entire modality franchise out of Chinese preclinical assets.
• Summit–Akeso — ivonescimab (ongoing). Summit continues to advance the PD-1/VEGF bispecific it licensed from Akeso (up to ~$5B total), including a U.S. BLA filing and a clinical-collaboration with Pfizer on ADC combinations. Why it matters: the asset that put PD-1/VEGF bispecifics on every BD team’s radar and triggered the wider race.

The pattern beneath the headlines is consistent: oncology and cardiometabolic dominate; deals are increasingly platform-level rather than single-asset; and upfronts are climbing toward Western norms. We unpack the structures in the outbound licensing tracker.

Recent Notable Deals at a Glance

Values are total potential (biobucks) unless an upfront is noted; treat contingent value with discipline. Figures are drawn from company disclosures and industry deal trackers.

NMPA Approvals

China’s regulator is approving innovative medicines at a record pace, and the mix is shifting toward home-grown innovation:

• ~120 new drugs cleared in 2025. The first triple-digit year, including roughly 40 biologics — mAbs, bispecifics, ADCs, and cell therapies. Why it matters: the regulatory throughput now matches the deal throughput; the supply of approvable, de-risked assets is structural, not a blip.
• Domestic developers outnumbered foreign arrivals. For the first time, the majority of new approvals came from Chinese companies. Why it matters: the innovation base is local, which is precisely what makes out-licensing the natural exit.
• Ivonescimab (Akeso) approved first-line in PD-L1+ NSCLC (2025). Cleared as monotherapy on the strength of a head-to-head Phase III that bettered pembrolizumab on PFS in the Chinese trial. Why it matters: a Chinese-origin biologic beating a global standard of care head-to-head is the kind of clinical signal that justifies the upfronts buyers are now paying.
• Mazdutide launched (2025). Reported as the world’s first approved GLP-1R/GCGR dual agonist. Why it matters: China is not only licensing into the metabolic wave but originating first-in-class assets within it.

For the running list of clearances and what they imply for asset availability, see our NMPA approvals tracker.

Capital Markets & IPOs

After a multi-year drought, the financing window — especially in Hong Kong — has reopened, which feeds directly back into deal capacity:

• Insilico Medicine — ~$293M HKEX IPO (December 2025). Hong Kong’s largest biotech IPO of the year, with cornerstone investors including Eli Lilly and Tencent, listed under the exchange’s newer rules for pre-revenue tech-bio names. Why it matters: public-market validation for the AI-drug-discovery thesis, and a template for the next cohort.
• Hengrui Pharmaceuticals — ~$1.3B HKEX listing (May 2025). The city’s largest pharma IPO in roughly five years. Why it matters: an established profitable player tapping offshore capital to fund globalization — a different signal from a pre-revenue float.
• The 18A / tech-bio listing wave continues. The HKEX’s 18A regime and STAR Market remain the primary public on-ramps for Chinese biotech, with names such as XtalPi already listed and a pipeline of filings behind them. Why it matters: a functioning IPO exit makes founders more willing to do partial, ex-China licensing rather than holding out for a full sale.

Re-opened capital markets matter to a licensor’s leverage. A company that can fund itself publicly is a tougher, more patient negotiating counterparty — worth remembering when you sit across the table.

Policy: VBP, NRDL & BIOSECURE

Three policy threads shape the economics of any China-linked asset: domestic price pressure (VBP), reimbursement access (NRDL), and the cross-border overhang (BIOSECURE).

• Volume-based procurement — 11th round (October 2025). All 55 tendered products were awarded, with the average price cut reportedly above 70% and, for the first time, winning prices kept confidential. Why it matters: VBP keeps compressing margins on commoditized generics, which is precisely why Chinese companies are racing to innovate and to out-license — the domestic generic market is a margin desert.
• NRDL 2025 negotiation (effective Jan 1, 2026). An 88% negotiation success rate added 114 drugs (including ~50 Class 1 innovative drugs), alongside the debut of a separate Commercial Health Insurance Innovative Drug catalog for higher-value therapies. Why it matters: faster reimbursement for genuine innovation — and a shortlist pass rate at a record low — confirms regulators are funneling money toward first-in-class over me-too assets.
• BIOSECURE enacted (December 2025). After years as a stalled standalone bill, BIOSECURE language passed within the FY2026 NDAA. The enacted text does not name specific companies; it references the Department of Defense’s list of Chinese military companies, with implementation guidance still pending. Why it matters: the law targets U.S. government-funded use of certain Chinese service and genomics providers — not asset licensing — so its direct bite on in-licensing a molecule is narrower than headlines imply, but the diligence bar rises.

We track the cross-border legal dimension in our BIOSECURE Act analysis and translate it into deal structure in our in-licensing service.

Notable Company Moves

Beyond the deals, several company-level developments are worth tracking as leading indicators:

• BeiGene became BeOne Medicines. The company rebranded (now trading as ONC on Nasdaq) as it positions itself as a global, rather than China-centric, oncology player. BRUKINSA (zanubrutinib) reported roughly $3.9B in 2025 global sales (up ~49%), with TEVIMBRA (tislelizumab) adding ~$737M. Why it matters: proof that a China-rooted company can build a globally commercial blockbuster — the aspirational endpoint many licensors now reference at the table.
• Akeso’s ivonescimab momentum. Beyond the first-line monotherapy approval, the NMPA accepted an sNDA for the chemo combination in squamous NSCLC, while partner Summit advanced global filings. Why it matters: the asset class (PD-1/VEGF bispecifics) is now the most contested in immuno-oncology BD.
• Hengrui’s globalization push. The GSK pact plus the HKEX listing mark a deliberate pivot from a domestic generics and innovation leader toward a globally licensing one. Why it matters: a bellwether for how the largest domestic players intend to monetize pipelines abroad.
• The AI-discovery cohort matures. Insilico’s IPO and its near-$120M Qilu cardiometabolic collaboration (January 2026) show AI-originated assets moving from novelty to bankable pipeline. Why it matters: see our Chinese AI drug discovery startups guide for the players behind this.

For the structured company-by-company landscape — who is public, who is partnered, and where the pipelines sit — see Top Chinese Biotech Companies 2026.

What We’re Watching Next

The items most likely to define the next several quarters, and why each is on our list:

• Whether 2026 out-licensing beats 2025. Trackers already flag 2026 as on pace to exceed the ~$136B record. If it does, the “China premium” in upfronts will harden — and entry points get more expensive for late movers.
• BIOSECURE implementation guidance. The statute is law, but the OMB guidance and any company-list updates (including proposed additions such as WuXi entities to the DoD list) will determine the real-world friction. We are watching for the first concrete guidance.
• The PD-1/VEGF bispecific class readouts. Pivotal Western-population data for ivonescimab and SSGJ-707 will either validate or temper the upfronts already paid — the single most consequential clinical question for recent China deal economics.
• The next wave of HKEX/STAR IPOs. A sustained listing window changes licensor leverage and the supply of independently financed counterparties.
• First-in-class metabolic assets. With mazdutide approved and obesity pipelines deep, watch which Chinese cardiometabolic assets attract the next mega-deal.

How to Read China Biotech News

A digest is only as useful as the judgement you bring to it. A few disciplines we apply to every China biotech headline — and recommend to anyone underwriting these assets:

• Separate biobucks from upfronts. A “$12 billion deal” is usually an option-and-milestone construct that pays out only if everything works. The upfront — and the equity, if any — is the number the buyer is actually willing to lose. Anchor on it.
• Distinguish China rights from global rights. Most landmark deals license ex-China rights; the originator keeps the home market. That changes the asset’s strategic value and the competitive dynamics entirely.
• Treat China-only clinical data as a starting point. A head-to-head win in a Chinese trial is a strong signal, but translatability to FDA/EMA standards and Western populations is a diligence question, not a given.
• Read policy as structural, not cyclical. VBP and NRDL are not weather; they are the climate that makes out-licensing rational. Companies are not waiting them out.
• Hold the geopolitics at the right altitude. BIOSECURE is real but narrower than the headlines; a molecule license is not a services contract. Conflating the two leads to both over-caution and unpleasant surprises.

The single most common error we see is reading China biotech news as either uniformly bullish (every AI-tagged asset a bargain) or uniformly suspect (uninvestable on political grounds). Both are lazy. The data — record deals, record approvals, re-opened capital markets, an enacted-but-narrow BIOSECURE — supports neither extreme. The correct posture is disciplined engagement: source selectively, diligence rigorously, and structure for the cross-border realities.

That is the work we do. If a specific deal, approval, or asset in this digest is relevant to your strategy — whether you are looking to in-license a Chinese asset, advise a Chinese company on out-licensing ex-China, or build a longer-term strategic partnership — talk to our team.